Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?

Novo Nordisk's stock has declined 70% from its 2024 high, trading at a 10x P/E ratio compared to its 5-year average of 24x. Despite losing market share to Eli Lilly in GLP-1 weight-loss drugs due to supply issues and efficacy concerns, the company is shifting to a volume-driven model with a pill version of its drug and has initiated a $2.2 billion stock buyback. The article suggests this valuation may represent an opportunity for long-term investors, supported by a 4.6% dividend yield.